ORGO
NASDAQ · Biotechnology
Organogenesis Holdings Inc
$2.47
+0.06 (+2.49%)
Financial Highlights (FY 2026)
Revenue
455.46M
Net Income
808.7K
Gross Margin
76.0%
Profit Margin
0.2%
Rev Growth
+1.0%
D/E Ratio
0.00
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 76.0% | 76.0% | 62.1% | 62.1% |
| Operating Margin | -0.3% | -0.2% | 10.4% | 9.2% |
| Profit Margin | 0.2% | 0.2% | 9.2% | 10.2% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 455.46M | 451.04M | 163.70M | 183.70M |
| Gross Profit | 346.10M | 342.74M | 101.68M | 114.10M |
| Operating Income | -1,229,735 | -1,096,020 | 17.05M | 16.82M |
| Net Income | 808.7K | 720.7K | 15.03M | 18.71M |
| Gross Margin | 76.0% | 76.0% | 62.1% | 62.1% |
| Operating Margin | -0.3% | -0.2% | 10.4% | 9.2% |
| Profit Margin | 0.2% | 0.2% | 9.2% | 10.2% |
| Rev Growth | +1.0% | +1.0% | +17.3% | -10.0% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 1.23M | 1.23M | 23.91M | 23.00M |
| Total Equity | 251.32M | 251.32M | 148.92M | 172.86M |
| D/E Ratio | 0.00 | 0.00 | 0.16 | 0.13 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 11.68M | 10.99M | 20.76M | 25.89M |
| Free Cash Flow | — | — | 17.26M | 13.87M |